The analysis of the prices and availability of medicines in different countries showed that the situation with drugs in the CIS is far from ideal. The price of a number of important drugs in Russia and neighboring countries is higher than in European countries. Some medications because of lack of interest of large pharmaceutical companies to buy in the CIS is impossible.
"In the CIS has a strong position of foreign pharmaceutical companies. Though in natural expression certain drugs of the local production covers about half of the market in value terms is dominated by the medicinal product of foreign production" - says the Deputy head of FAS Anatoly Gomolin.
There should be closer relationship between the pharmaceutical giants from the European Union and suppliers from Russia and CIS. Require certain measures to simplify the registration of drugs from abroad, according to Homalin.